Renaissance Technologies LLC Boosts Holdings in Xilio Therapeutics, Inc. (NASDAQ:XLO)

Renaissance Technologies LLC raised its holdings in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) by 11.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 296,617 shares of the company’s stock after buying an additional 30,317 shares during the period. Renaissance Technologies LLC owned about 0.67% of Xilio Therapeutics worth $283,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Raymond James Financial Inc. bought a new position in Xilio Therapeutics in the 4th quarter worth $48,000. Geode Capital Management LLC raised its stake in shares of Xilio Therapeutics by 85.0% in the third quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock worth $266,000 after buying an additional 155,337 shares during the period. Finally, Takeda Pharmaceutical Co. Ltd. purchased a new position in shares of Xilio Therapeutics during the 4th quarter valued at about $1,416,000. 54.29% of the stock is currently owned by institutional investors.

Xilio Therapeutics Trading Down 1.4 %

Shares of NASDAQ:XLO opened at $0.74 on Tuesday. The company has a market cap of $38.30 million, a PE ratio of -0.43 and a beta of -0.27. The stock has a 50 day moving average of $0.77 and a 200 day moving average of $0.92. Xilio Therapeutics, Inc. has a 12-month low of $0.62 and a 12-month high of $1.70.

Xilio Therapeutics (NASDAQ:XLO) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.02. The business had revenue of $1.72 million during the quarter, compared to the consensus estimate of $2.26 million. Equities research analysts predict that Xilio Therapeutics, Inc. will post -1.14 earnings per share for the current fiscal year.

Xilio Therapeutics Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.